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Abstract The oral epithelium functions as a mechanical and protective barrier to resist
bacterial infection. Several types of host defense peptides (HDPs), including defensins, cathe-
licidins, and histatins, may have important roles in innate host defense. HDPs, which are mostly
cationic and have amphipathic structures, provide non-specific, rapid defense against invading
pathogens.
Human cationic antimicrobial protein 18 kDa (hCAP18/LL-37) is the only member of the
cathelicidin family identified in humans thus far. Proteolytic processing releases LL-37 from its
inactive precursor hCAP18/LL-37 to initiate its antimicrobial activity. As its name implies, LL-37 is
made up of 37 amino acids. Various immune and epithelial cells secrete hCAP18/LL-37, and its
level is altered in response to cariogenic, periodontal, congenital, inflammatory, and malignant
diseases in the oral region. Human cathelicidin peptide, LL-37 exhibits antimicrobial activity
against bacteria that cause oral pathological conditions, including cariogenic disease and
periodontitis. Altered expression of hCAP18/LL-37 was observed in oral inflammatory lesions
with and without microbial infection or oral cancer. Treatment with hCAP18/LL-37 may be useful
in infectious, inflammatory, and cancerous diseases.
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68 K. OkumuraTable 1 Structure-based classification of HDPs.
Representative peptides Origin Refs.
b-Sheet
a-Defensins
[HNP1—4, HD5, HD6]
Human [7—9]
b-Defensins [HBD1—4] Human [10]
u-Defensin Rhesus
monkeys
[11]
Tachyplesins Horseshoe
crab
[12]
*Protegrins Pig [13]
a-Helical
*hCAP18/LL-37 Human [14—16]
*BMAP-27,28 Bovine [17]
Cecropins Silk moth [19,117]
Magainins Frog [20]
Dermaseptin Frog [21]
Buforin I, II Toad [22]
Loop
*Dodecapeptide Bovine [23]
Thanatin Hemipteran [24]
Brevinins Frog [25,26]
Extended
*Bac5, 7 (Pro- and Arg-rich) Cow [27]
*PR-39 (Pro- and Arg-rich) Pig [28]
*Indolicidin (Trp-rich) Cow [29]
Histatins (his-rich) Human [30]
Peptides derived from cathelicidins are indicated by asterisks.Introduction
The human oral cavity is constantly exposed to a variety of
microorganisms that could colonize and cause disease. Resis-
tance to oral bacterial infection is offered by the oral mucosa
membrane, which acts as a mechanical barrier, and saliva,
which contains unique HDPs (also termed antimicrobial pep-
tides) and increases mechanical action. Additionally, the oral
mucosa membrane serves as a mechanical and physical
shield. The mechanical shield of the oral epithelium consists
of stratified keratinocytes, which form a strengthened struc-
ture [1]. The physical shield of the oral epithelium also
initiates an active immunological response by presenting
antigens and producing cytokines and HDPs [2]. Several types
of HDPs, including defensins, cathelicidins, and histatins,
may have important roles in innate host defense. HDPs, which
are mostly cationic and have amphipathic structures, provide
non-specific and rapid defense against invading pathogens. In
human saliva, histatins are the major HDPs that are consti-
tutively produced and directly secreted by the submandib-
ular, sublingual, and parotid glands. The salivary glands also
secrete small amounts of defensins and cathelicidin; these
peptides are also produced by neutrophils and oral epithelial
cells. Certain types of defensins and cathelicidin are indu-
cible by inflammatory cytokines, indicating that these pep-
tides may be of crucial importance under inflammatory
conditions [3,4]. All these peptides have a broad range of
biological properties. In addition to antimicrobial, antifun-
gal, and antiviral activities, some of these peptides also
possess antitumor or immunomodulatory properties.
This review focuses on human cathelicidin in the oral
cavity and discusses its importance and potential in the
clinical therapy of oral diseases.
The classification and the molecular
structure of HDPs
HDPs are diverse in their sequence and structures. To date,
almost 1000 naturally occurring HDPs from bacteria, fungi,
plants, invertebrates, amphibians, and mammals have been
described (http://www.bbcm.univ.trieste.it/tossi/amsdb.
html, and http://aps.unmc.edu/AP/main.php). They are
generally amphipathic, small (12—50 amino acids), and have
at least two positive charges (as arginine or lysine residues).
The diversity of HDPs discovered is so great that it is only
possible to categorize them broadly, on the basis of their
secondary structure [5]. Basically, HDPs can be classified
according to four characteristic structures [6]: (1) b-sheetstructures stabilized with two or three disulfide bonds such as
mammalian defensins, (2) amphipathic a-helical structures
such as human cathelicidin (3) loop structures containing one
disulfide bound such as dodecapeptide, and (4) extended
structures such as PR-39 and histatins (Table 1) [7—30].
Three families of HDPs are expressed predominantly in
humans: defensins, cathelicidin, and histatins. Defensins are
small cysteine-rich HDPs that mainly form b-sheet structures
stabilized by several (usually three) conserved intramolecu-
lar cysteine disulfide bounds and are typically 28—44 amino-
acid residues. Three subfamilies, a-, b-, and u-defensins, are
expressed in vertebrates [9]. In humans, u-defensin mRNA is
expressed; however, lack the corresponding peptides since
the human u-defensin gene contains a stop codon in the signal
sequence that aborts translation [31]. The insect and plant
defensins contain six or eight cysteines in the disulfide
Human cathelicidin therapeutic potential 69bridge. In addition, insect defensins contain a-helical dis-
ulfide bridges connected to a b-sheet structure stabilized by
cysteine, which differs from vertebrate defensins [9]. Cathe-
licidins comprise a large number of precursors of HDPs that
typically contain a conserved N-terminal sequence region
that shares high homology with the proregion of cathelin, a
cathepsin L inhibitor (hence the term cath-e-L-in). The C-
terminal antimicrobial domain of different cathelicidin pre-
cursors varies widely in terms of sequence, composition, and
structure. Processed cathelicidin peptides range from 12 to
80 or more amino acid residues in size and may have b-sheet,
a-helical, loop, or extended structures [32,33] (Table 1). The
only human cathelicidin, antimicrobial peptide LL-37, is
composed of 37 amino acid residues and a cysteine-free
peptide that can adopt an amphipathic a-helical conforma-
tion [34]. In contrast, histatins are family of small cationic
histidine-rich peptides amounting to 3—5 kDa in the human
saliva [35]. The major family members of histatins 1 and 3 are
products of human genes alone: these are HIS1 and HIS2,
respectively [36]. Histatin 5 originates from histatin 3 by
post-translational processing. Histatin 1, 3, and 5 have linear
extended structures containing 38, 32, and 24 amino acid
residues, respectively, and the sequence of the first 22 amino
acids of each histatin is identical [37].
The molecular structure of human
cathelicidin hCAP18/LL-37
Cathelicidins were first discovered in mammals but have
been recently found in chickens and three species of fish
(rainbow trout, Atlantic salmon, and hagfish). In particular,
hagfish remarkably lacks essential components of adaptive
immunity. The presence of cathelicidins in this very ancient
species may indicate that cathelicidin genes developed early
in vertebrate phylogeny [38].
In humans, only one cathelicidin has been found from the
myeloid bone marrow cDNA [14—16] and isolated from neu-
trophils [15]. In the human genome, cathelicidin exons 1—4
are found on chromosome 3p21. These are transcribed as a
single gene, CAMP (cathelicidin antimicrobial peptide),
which translates to an 18 kDa pre-pro-protein, referred to
as hCAP18 [15,16]. The other term used to describe the
protein is hCAP18/LL-37, because this protein is character-
ized by a N-terminal signal peptide (30 amino acid residues),
a highly conserved prosequence (103 amino acid residues)
called the cathelin like domain and a mature antimicrobial
peptide named LL-37 (37 amino acid residues with Leu-Leu at
the N-terminus) at the C-terminal domain [16] (Fig. 1). LL-37
has a net positive charge of +6 at the physiological pH, a
hydrophobic N-terminal domain, and a a-helical conforma-
tion most pronounced in the presence of negatively charged
lipids [39]. LL-37 is produced from the C-terminal domain of
the hCAP18/LL-37 precursor protein by proteolytic cleavage.[()TD$FIG]
Signal
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Figure 1 Schematic diagram of human CAP18 showing the signal peThe hCAP18/LL-37 from specific granules of neutrophils is
processed to active peptides LL-37 following exposure to the
serine protease, as proteinase 3 from azurophil granules after
exocytosis. Proteinase 3 is cleaved at the hCAP18/LL-37
between the alanyl and leucyl residue [40]. However, pro-
teinase 3 is expressed only myeloid cells and not epithelial
cells. In recently study, the serine proteases stratum cor-
neum tryptic enzyme (SCTE, kallikrein 5) and stratum cor-
neum chymotryptic protease (SCCE, kallikrein 7) activates
the precursor protein hCAP18/LL-37 on the skin surface [41].
In addition, the prostate-derived protenase gastricsin (pepsin
C) in the presence of varginal fluid at low pH, can also process
epididymal-derived hCAP18/LL-37 in seminal plasma to func-
tionally active ALL-38 [42].
Tissue distribution of hCAP18/LL-37
Most HDPs (bacterial/permeability increasing protein: BPI,
azurocidin: CAP37, and a-defensins) are localized in azur-
ophil granules [43—45]. In contrast, cathelicidin hCAP18/LL-
37 is a major protein of the specific granules of immature
neutrophils [46]. However, hCAP18/LL-37 shown to be pro-
duced in various blood cell populations, including NK cells,
gdTcells, B cells, monocytes [47], and mast cells by using RT-
PCR, in situ hybridization, and immunohistochemical detec-
tion [48]. In addition, hCAP18/LL-37 is consistently expressed
at both the mRNA and protein levels in the squamous epithe-
lia of the airways, mouth, tongue, esophagus, intestine,
cervix, and vagina. This peptide is widely produced in squa-
mous epithelia; this suggests a role for this peptide in
epithelial antimicrobial defense [49—51]. Furthermore,
hCAP18/LL-37 was detected in the saliva and salivary glands,
specifically in the acinar cells of the submandibular gland and
palatine minor glands as well as in the lingual epithelium and
palatal mucosa [52]. Additionally, it can be found in a number
of other body fluids, including sweat, gastric juices, semen,
plasma, airway surface fluid, and breast milk [53,54].
Epithelia not only provide a physical barrier between the
body and the environment but also participate in the main-
tenance, renewal, and defense of these surfaces. Indeed,
epithelia were found to be the second major producer of
hCAP18/LL-37 after defensins [50,55]. In normal oral epithe-
lium, hCAP18/LL-37 mRNA is strongly expressed in the basal
layers and is decreased toward the surface, although its
peptide immunoreactivity is also seen in the supra-basal
layers [49] (Fig. 2(A)). The hCAP18/LL-37 mRNA and its
protein, interestingly, are undetectable in normal skin
[55,56]. One may argue that constitutive expression of its
peptide may be more critical in epithelia lacking the outer
keratinized cover in oral epithelial cells. The hCAP18/LL-37 is
stored in secretory granules called the lamellar bodies of
keratinocytes, as determined by immunogold electron micro-
scopy [57].37
ids
Antimicrobial Domain
HOOC
ptide, N-terminal domain, and C-terminal LPS-binding domains.
[()TD$FIG]
Figure 2 In noninflammatory and oral lichen planus of the gingival mucosa, hCAP18/LL-37 is expressed. (A) Noninflammatory gingival
mucosa demonstrates positive immunoreactivity for hCAP18/LL-37 predominantly found in the basal epithelial layer. (B) Oral lichen
planus demonstrates strong immunoreactivity for hCAP18/LL-37 in the superficial epithelial layer. (C) hCAP18/LL-37 immunoreactive
stroma cells in the noninflammatory gingiva. (D) High-power view of superficial epithelial layer, same as in panel B. Bars: A and B,
100 mm; C and D, 20 mm.
70 K. OkumuraVarious biological activities of the hCAP18/
LL-37 peptide
Mechanism of action and antimicrobial activity
HDPs-mediated microbial killing can be rapid: some linear a-
helical peptides kill microbes very quickly [6]. For example,
cecropin P1 and PR-39 kill bacteria within 25 min [58].
Regardless of the specific antimicrobial mechanism, specific
steps must occur in inducing bacterial death.
Antimicrobial activity occurs through several mechan-
isms. The first step in HDPs-mediated function is attraction.
Attraction is considered to occur when the initial interaction
between the cationic peptides first occur through electro-
static interactions with the negatively charged bacterial
membrane. Interestingly, HDPs show significantly lower cyto-
toxicity to host cells because their membranes posses a high
amount of cholesterol. The second step is attachment, where
the peptides traverse the exterior capsular polysaccharides
to reach the inner lipid layer. It is shown that two physiolo-
gically distinct states occur during this peptide-membrane
interaction. At low peptide/lipid ratios, b-sheet (defensins)
and a-helical (LL-37) peptides first embed into the lipid head
groups in a functionally inactive state, stretching the mem-brane. At high peptide/lipid ratios, peptides orient perpen-
dicularly and insert into the bilayer [59]. After insertion,
antimicrobial peptides act via membrane permeation. Three
main models of the action of membrane perturbation by HDPs
have been proposed: the barrel-stave model, carpet model,
and toroidal-pore model. In the barrel-stave model, peptide
helices form a bundle in the membrane with a central lumen,
very similar to a barrel, with the helical peptides as the
staves. This model explains the activity of antimicrobial
peptides such as the fungus antimicrobial peptide, alamethi-
cin. In the carpet model, the peptides accumulate on the
bilayer surface. They are electrostatically attracted to the
anionic phospholipid head groups at numerous sites covering
the surface of the membrane in a carpet-like manner. At high
concentrations, the peptides are believed to disrupt the
bilayer acting like a detergent, resulting in the formation
of micelles. This type of transmembrane pore is induced by
LL-37. The toroidal pore model combines the action of the
two previous models and begins with aggregation on the
membrane surface. The peptides insert into the membrane
perpendicularly and induce continuous bending of the lipid
monolayers through the pore lead to the water core to be
lined by both the inserted peptides and the lipid head groups.
During this action, the polar faces of the peptides associate
with the polar head groups of the lipids, resulting in a
Human cathelicidin therapeutic potential 71continuous bend that connects the two leaflets of the mem-
brane. Thus, toroidal pore formations in themembrane result
in the lipids forming micelles and subsequent membrane
disruption. This model explains the activity of antimicrobial
peptides such as magainins and protegrins [60].
Its antimicrobial properties led to the initial identification
of hCAP18/LL-37 [39]. It exhibits antimicrobial activity
against both gram-positive and gram-negative bacterial
strains. The minimal inhibitory concentration (MIC) for LL-
37 against these pathogens can range to less than 10 mg/ml
[34]. This peptide is active against clinically important
strains of gram-negative bacteria and periodontal pathogens
such as A. actinomycetemcomitans and Capnocytophaga
[61]. Similarly, we showed that the LL-37-derived 27-mer
synthetic peptide (hCAP18109—135) and its analogues (LL/
CAP18 and FF/CAP18) killed Porphyromonas and Prevotella
species within a short time and with a low peptide concen-
tration [62] (Fig. 3). Additionally, LL-37 peptide is capable of
killing gram-negative oral streptococci, including Strepto-
coccus mutans, S. sanguinis, S. salivarius, and S. mitis. The
LL-37 is particularly effective in killing these streptococci,
especially S. mutans, when they act as cariogenic pathogens
[63]. Our study demonstrated that the LL-37-derived syn-
thetic peptides exerted potent antimicrobial activity against
Streptococcus sanguis isolated from patients with Behc¸et’s[()TD$FIG]
Figure 3 Killing of Porphyromonas in the presence of various
concentrations of hCAP18-derived peptides. hCAP18-derived
peptides demonstrated antimicrobial activity against P. gingiva-
lis 381 (A). hCAP18-derived peptides also demonstrated antimi-
crobial activity against P. circumdentaria NCTC12469 (B).
Incubated for 15 min in HBSS (pH 7.4) for 37 8C. The points
and error bars are expressed as the mean and standard deviation
of three independent assays. * hCAP18109—135, ~ LL/CAP18,
and & FF/CAP18 (see ref. [44]).disease (BD), thereby producing a stronger killing activity
[64] (Fig. 4). Hence, LL-37 is related to oral mucosal defense,
and the regulated expression and production of this peptide
can be important for the suppression of BD. Furthermore, this
antimicrobial activity is augmented by a- or b-defensins in
vitro [65]. These data suggest that the LL-37 peptide acts
synergistically under in vivo conditions to form an efficient
barrier against microbial invasion.
In the oral cavity, microbes are exposed to saliva and
serum, which contain salt and reduce the antimirobial activ-
ity of b-defensins by 50% of the activity observed under
control (salt-free) conditions [63]. In contrast, cathelicidin
LL-37 are active against several bacteria in high salt media
[34,65,66], supporting its capacity to function under a vari-
ety of physiological conditions. Additionally, high ionic con-
centrations are generally found in body fluids, including the
saliva of patients with cystic fibrosis [67]. In a cystic fibrosis
xenograft model, gene transfer of hCAP18/LL-37 restored
bacterial killing to normal levels [68]. This report suggests
that hCAP18/LL-37 may confer protection against bacterial
infections in vivo.
In Candida albicans, LL-37 can disrupt the cell wall and the
cell membrane. Thus, peptide-induced membrane permea-
bilization increases the inhibition of C. albicans growth [69—
71].
HDPs are known to contain some antiviral activity. For
example, b-sheet peptides such as defensins, tachyplesin,
and protegrins provoked remarkable inactivation of HSV [72].
Furthermore, a-helical peptide as LL-37 inhibits virus repli-
cation against vaccinia (smallpox) virus [73]. In addition, LL-
37 exhibits antiviral activity against HSV-1 in corneal and
conjunctival epithelia [74].
Peptide interaction with tumor cells and
antitumor activity
Existing chemotherapeutic drugs that are widely used in
cancer treatment have the severe side effect of nonspecific
cytotoxicity. These agents target any rapidly dividing cells,
without discriminating between healthy and cancerous cells.
Furthermore, many cancers eventually become resistant to
conventional chemotherapy through selection for multidrug-
resistant variants [75]. Thus, there is an urgent need to
develop new antitumor drugs with new modes of action that
selectively target the cancerous cells.
Most HDPs have a cationic amphipathic structure, and
they preferentially bind and insert into the negatively
charged surfaces of bacterial cell membranes. The conse-
quent destabilization of the membranes disturbs electrolyte
balance and causes leakage of the intercellular contents,
leading to cell death. Normal mammalian cell membranes
generally have a neutral net charge, and their membranes
are enriched in phosphatidylethanolamine (PE), phosphati-
dylcholine (PC), sphingomyelin (SM), and cholesterol. In
contrast, bacterial cell membranes are negatively charged
with higher proportions of phosphatidylglycerol (PG), cardi-
olipin (CL), and phosphatidylserine (PS), and have lower
cholesterol content [76]. Thus, differences between the host
and bacterial cell membranes exist, and these present poten-
tially selective targets for HDPs.
Several HDPs preferentially disrupt bacterial and cancer
cell membranes rather than host eukaryotic cell membranes
[()TD$FIG]
Figure 4 Antimicrobial activity of hCAP18-derived peptides–—IC50. The IC50 shows that hCAP18 is active against all strains at
concentrations ranging from 0.5 to 8.4 mg/ml. The IC50 of the CAP18 analog peptide (LL/CAP18 or FF/CAP18) is showed a maximum 10-
fold stronger potential than that of hCAP18109—135 (see ref. [45]).
72 K. Okumura[77,78]. The cancer cell membranes contain a large amount
of negatively charged PS, which is more negative than that of
normal eukaryotic cells [79]. Therefore, it has been sug-
gested that the increase in negatively charged PS in the
cancer cell membranes makes them more susceptible to
the cytotoxicity of the peptides than normal eukaryotic cells
[80]. In addition, these peptides that disrupt target cell
membranes as part of their killing effect show irreversible
activity [81,82].
The existence of antitumor activity was first proven in a
study of the antimicrobial peptide magainin (a non-hemolytic
a-helical peptide) and its synthetic analogues, which are
active against hematopoietic and solid tumors at concentra-
tions that are moderately nontoxic to normal cells [83].
Similarly, HDPs act via a non-receptor-mediated pathway
against the target cell membranes as do melittin (a non-
selective cytotoxic a-helical peptide), cecropin (a non-hemo-
lytic a-helical peptide), and androctonin (a non-hemolytic b-
sheeted peptide) [84,85]. Therefore, the biological activity
shown by these peptides suggests the existence of killing
mechanisms that involve perturbation of the plasma mem-
brane, inducing necrosis. Membrane-active peptides can
induce the permeabilization ofmitochondria, triggering apop-
tosis [82]. A cationic membrane-active antimicrobial peptide,
CNGRC-GG-D(KLAKLAK)2, shows antitumor activity via the
mitochondrial pathway of apoptosis [86]. Similarly, tachyple-
sin, a heptadecameric cationic antimicrobial peptide, could
interactwith themitochondrialmembranesof cancer cells and
induce apoptosis [87,88]. Thus, the cationic antimicrobial
peptides exhibit antitumor activity. In the cathelicidin family,
the bovine produced BMAP-27 and BMAP-28 have been shown
to inducemembrane permeabilization and apoptosis in human
leukemic tumor cells and normal proliferating but not resting
lymphocytes [89,90]. This is associated with cathelicidin pep-
tide-induced membrane permeabilization and is followed by
programmed cell death. This indicates that BMAP-28 induced
mitochondrial membrane permeability and then caused mito-
chondrial depolarization and released cytochrome c, leading
to apoptosis [90].
We have previously synthesized a 27-amino acid sequence
from the C-terminal domain of hCAP18/LL-37 and described
its antimicrobial activity against Porphyromonas and Prevo-
tella species [62]. This peptide is designated hCAP18109—135
and consists of the active domain, as LL-37. In our recent
study, hCAP18109—135 induced apoptotic cell death of squa-mous cell carcinoma cells, but not gingival fibroblasts or
normal keratinocytes and HaCaT cells [91]. The hCAP18109—
135 induced apoptotic cell death was attributed to a caspase-
independent pathway (Fig. 5, data unpublished). Further-
more, we demonstrated a correlation between different
apoptotic events affecting the mitochondria, cytosol, and
nuclei following hCAP18109—135 inductions. In order to exam-
ine the apoptotic effect of hCAP18109—135 on human squa-
mous cell carcinoma SAS-H1 cells, the peptide was added at a
concentration of 40 mg/ml in the presence of 10% fetal
bovine serum. We showed that hCAP18109—135 elicited the
translocation of Bax to the mitochondria and endonuclease G
to the cytosol. Thus, in peptide-induced cell death, Bax-
dependent endonuclease G release plays a role in caspase-
independent oligonucleosomal DNA fragmentation (Figs. 6
and 7, data unpublished). The active domain peptide LL-37 of
hCAP18/LL-37 is also shown to induce the apoptosis of human
lung carcinoma A549 cells, SV40-transformed, immortalized
16HBE4o-human airway epithelial cells, and primary human
bronchial epithelial cells [92,93]. However, in contrast to our
observations, the LL-37 induced apoptosis via caspase-3
activation; these data indicate caspase-dependent pro-
grammed cell death. Importantly, this peptide suppressed
the apoptosis of neutrophils [94]. In this context, the
mechanisms involved in the apoptotic and antiapoptotic
actions of these peptides remain to be determined.
Taken together, these studies show that the mechanism of
tumor cell killing by host defense peptides is poorly under-
stood. However, in particular, human cathelicidin peptides
have selective cytotoxicity toward tumor cells and may be
useful antitumor therapeutic agents.
Other biological activities
A previous study showed that LL-37 protects against endotoxin
shock [95]. Lipopolysaccharide (LPS) is a cell membrane com-
ponent of gram-negative bacteria. LPS has strong biological
activity and plays a key role in the pathogenesis of endotoxin
shock associated with various syndromes [96,97]. LPS induces
monocytes, macrophages, and other types of cells to produce
and release potent pro-inflammatory cytokines. However, LL-
37 can neutralize the biological activity of LPS by binding to it
withhigher affinity [98—100]. Indeed,we foundthat theLL-37-
derived 27-mer synthetic peptide (hCAP18109—135) suppressed
development of endotoxin-induced uveitis in vivo in rats
[()TD$FIG]
Figure 6 hCAP18-derived peptide induces alterations in the Bax/Bcl-2 ratio and mitochondrial release proteins of SAS-H1 cells. SAS-
H1 cells were treatedwith 40 mg/ml hCAP18109—135 for the indicated time points. M:mitochondrial fraction, C: cytosolic fraction. Equal
amounts of cell lysates were separated by SDS-PAGE, followed by immunoblotting with anti Bax and ant Bcl-s antibodies (A). Cells were
treated for the indicated time points with hCAP18109—135. N: nuclear fraction, M:mitochondrial fraction, and C: cytosolic fraction were
analyzed by immunoblotting for the presence of AIF, Endo G, HtraA2/Omi, and cytochrome c (B).
[()TD$FIG]
Figure 5 hCAP18-derived peptide induced morphological alteration in tumor cells. The SCC cells, SAS-H1 cells, were cultured in the
absence (top) or presence (bottom) of 40 mg/ml hCAP18109—135 for 24 h and then photographed using digital image capture and a phase-
contrast light microscope (A). Transmission electron microscopic micrographs showing differences in SAS-H1 cells and mitochondria
morphology upon hCAP18109—135 exposure. Untreated SAS-H1 cells and mitochondria (top) versus hCAP18109—135-treated SAS-H1 cells
andmitochondria (bottom) showing severe ultrastructural changes such as disorganization and swelling of themitochondrial organelle.
Bars: 1 mm (B).
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[()TD$FIG]
Figure 7 hCAP18-derived peptide induces apoptosis in SAS-H1 cells. Agarose gel electrophoresis analysis of DNA fragmentation in
SAS-H1 cells following treatment with complete medium alone or in the presence of 40 mg/ml hCAP18109—135 for 6, 24, 36, and 48 h (A).
TUNEL assay on peptide-treated SAS-H1 cells. SAS-H1 cells were cultured in the absence (top) or presence (bottom) of 40 mg/ml
hCAP18109—135 for 48 h and then observed using confocal laser microscopy. DAPI: nucleic acid staining (B).
74 K. Okumura[101]. Therefore, the hCAP18109—135 suppresses the onset of
LPS-triggered inflammatory reactions by binding directly to
LPS.
LL-37 demonstrates chemotactic activity for T lympho-
cyte cells, monocytes, and neutrophils [102], thus attracting
even more leukocytes to the site of increased LL-37 concen-
tration in inflamed or infected tissue. In addition, mast cells,
which form an important tissue-localized part of innate
immunity, exhibited LL-37-induced migration, histamine
release, and intracellular Ca2+ mobilization [103]. LL-37
was proven to activate at least three different receptors,
namely FPRL-1 (formyl peptide receptor-like 1) [102,103],
EGFR (epidermal growth factor receptor) [104], and the
purinegic receptor P2X7 [105]. Furthermore, a vitamin D
responsive element is identified in the human cathelicidin
gene CAMP promoter region [106]. The vitamin D3 signaling
cascade that leads to increased cathelicidin expression has
been identified [107,108]. LL-37 modulates dendritic cell
(DC) differentiation and enhances the secretion of helper
T cell type 1 (Th-1)-inducing cytokines in vitro [109]. These
results suggest that hCAP18/LL-37 bridges the innate and
adaptive immune responses. Recently, the hCAP18/LL-37
peptide has been identified as the key factor that mediates
the activation of plasmacytoid dendritic cells (pDCs) in psor-
iasis, a common autoimmune skin disease. pDCs do not
normally respond to self-DNA, but binding to hCAP18/LL-
37 converted DNA into a potent stimulus for pDC activation.
The hCAP18/LL-37 and self-DNA complexes signaled through
TLR9 and elicited interferon (IFN)-a release from pDCs. IFN-a
subsequently activated a T-cell response that could lead to
inflammation [110]. Interestingly, pDCs are also found in oral
lichen planus (OLP) and in periodontitis [111,112]. In parti-
cular, significant recruitment of pDCs producing IFN-a within
the lichenoid inflammatory infiltrate and close cell—cell
contacts between pDCs and mature dendritic cells (DCs) have
been demonstrated. These data indicate that recruitment of
different subtypes of DC, including pDCs, may play a pivotal
role in the development of the lichenoid inflammatory infil-trate that typically occurs in OLP. We hypothesize that by
analogy with the hCAP18/LL-37 and self-DNA complexes that
activate pDCs in psoriasis, its peptide increases in OLP.
Binding of self-DNA released from damaged or apoptotic cells
to hCAP18/LL-37 may be potentially developed as therapies
for OLP and other chronic inflammatory diseases.
Additionally, hCAP18/LL-37 induced angiogenesis, and its
peptide resulted in neovascularization both in the chorioal-
lantoic membrane assay and in a rabbit hind-limb ischemia
[113]. This peptide directly activated endothelial cells to
proliferate and form vessel-like structures in human
endothelial cells, HUVECs, and shown to cause endothelial
sprouting from hamster aortic rings. The angiogenic activity
of hCAP18/LL-37 appears to be mediated by the interaction
of peptide with FPRL-1 in endothelial cells.
The involvement of hCAP18/LL-37 in the oral
diseases
Caries and periodontitis
It has been demonstrated that human b-defensin-3 (hBD-3),
hCAP18/LL-37, and a-defensins are present in the mg/ml
range in children’s saliva. The concentration of a-defensins
was significantly higher in children with no caries than in
those with caries, whereas the concentration of hCAP18/LL-
37 and hBD-3 did not correlate with caries [114]. In contrast,
the expression of hCAP18/LL-37 was upregulated in the
inflamed gingival tissue in comparison with healthy gingival
tissue and was correlated positively with the depth of the
gingival crevice [115], indicating that hCAP18/LL-37 expres-
sion in the gingival tissue is associated with the severity of
periodontal disease. In addition, there are variations in the
responses of oral epithelial cells to different bacteria and in
the sensitivity of oral flora to the peptides [116]. For exam-
ple, Prevotella intermedia induced the expression of hCAP-
18/LL-37 and hBD-1, hBD-2, and hBD-3; Fusobacterium
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hBD-2. Other species associated with periodontal disease,
such as Tannerella forsythia and Treponema denticola, either
did not induce expression or caused a down-regulation of
steady state mRNA levels. Expression of hCAP18/LL-37 in the
gingival epithelial cells was similar; P. gingivalis did not
induce expression, whereas A. actinomycetemcomitans, F.
nucleatum, P. intermedia, and E. corrodens upregulated the
expression of hCAP18/LL-37 [115].
Periodontitis associated with congenital diseases
In severe congenital neutropenia (SCN, or morbus Kostman)
was associated with hCAP18/LL-37 deficiency, and the
reduced levels of a-defensins (HNP1-3) were also found in
the neutrophils of patients with SCN. Furthermore, hCAP18/
LL-37 is completely absent from the plasma and saliva of
these patients; consequently, these patients present chronic
periodontitis and overgrowth of Actinobacillus actinomyce-
temcomitans. Surprisingly, hCAP18/LL-37 has been reported
to have antimicrobial activity against A. actinomycetemco-
mitans, supporting the hypothesis that the deficiency of its
peptide may result in periodontitis. In addition, despite
normalized absolute neutrophil count levels, G-CSF-treated
SCN patients still often have periodontitis [117,118]. Accord-
ing to the maturation cycle of neutrophils, defensins are
predominantly detected at the promyelocyte stage, when
primary granules mature. In contrast to hCAP18/LL-37, which
is primarily detected at the myelocyte stage, when second-
ary granules mature [119]. Recently, HAX1 gene mutations in
SCN patients that result in increased apoptosis in myeloid
cells have been identified. The HAX1 gene encodes the
hematopoietic cell-specific protein 1 (HS1)-associate protein
X-1 (HAX-1), which has been regulated in apoptosis [120].
Thus, deficiency of hCAP18/LL-37 may be associated with
maturation arrest in myelopoiesis. Similarly, severe period-
ontitis is found in the Papillon—Lefe`vre syndrome (PLS), an
inheritable disease caused by loss-of-function mutations in
the cathepsin C gene. Cathepsin C is the activator of serine
proteinases, elastase, cathepsin G, and proteinase 3. These
patients have been recently found to lack active neutrophil-
derived serine proteases. The neutrophils of PLS patients
release reduced levels of mature hCAP18/LL-37 because
serine proteinases are needed to convert the neutrophil-
derived hCAP18/LL-37 into the mature peptide that pos-
sesses antimicrobial activity [121].
These studies suggest that hCAP18/LL-37 plays an impor-
tant role in innate immunity against periodontal pathogens.
Inflammatory epithelial diseases
In keratinized epithelial cells, hCAP18/LL-37 is inducible with
inflammatory disorders, psoriasis, and nickel allergy [50].
Under inflammatory conditions, the epidermis showed abun-
dant immunohistochemical staining of its peptide, while the
healthy dermis did not show the presence of the peptide. In
non-keratinized epithelial cells, under conditions of dyspla-
sia and inflammatory cervix of the uterus, the strongest
expression of hCAP18/LL-37 was detected at both the mRNA
and protein levels in the upper spinous and granular layers
toward the surface [49]. In fact, we found that the oral lichenplanus (OLP) expresses more intense immunohistochemical
staining for the hCAP18/LL-37 peptide than the normal
epithelium (Fig. 2, unpublished data). Similarly, OLP showed
intense immunohistochemical staining of b-defensin-2 (hBD-
2) [122]. This increased expression is not related to microbial
infection. For example, hCAP18/LL-37 mRNA and its peptide
are rapidly expressed in the skin at the site of injury. More-
over, expression of hCAP18/LL-37 in the keratinocytes
occurred in response to a sterile surgical incision [56]. The
growth factors important in wound healing, such as insulin-
like growth factor I (IGF-I) and transforming growth factor-a
(TGF-a), induce the expression of hCAP18/LL-37 and b-
defensin-3 (hBD-3), respectively, in human keratinocytes
[123]. In addition, IGF-I and TGF-a expression is increased
in the psoriatic epidermis and during wound healing [124—
127]. The generation of these growth factors in inflamed
lesions without microbial infection may have contributed to
this response. In contrast, in cases of inflammatory disease,
atopic dermatitis shows significantly lower expression of
hCAP18/LL-37 and hBD-2 than psoriasis [128]. Similarly,
hCAP18/LL-37 expression has been shown to decrease in
the chronic ulcer epithelium [129]. Decreased expression
of these peptides can explain the increased susceptibility
to microbial colonization and infection. Consequently, the
level of hCAP18/LL-37 expression may be related to the
causes of a disease. For instance, at low concentrations of
hCAP18/LL-37 found in normal human epithelia, its peptide
could function as an immune watchdog and in cases of high
concentrations, when hCAP18/LL-37 is induced by bacteria,
bacterial products, or inflammatory cytokines, its peptide
could function to promote the migration of immune cells to
help control the infection.
Malignant tumors
Alterations in hBD expression in oral squamous cell carcinoma
(SCC) have been shown. The expression levels of hBD-1 and
hBD-2 varied among cell lines derived from human oral SCC.
Although high hBD-2 mRNA expression is detected in all cell
lines examined, some of the cell lines did not show hBD-1
mRNA expression [130]. In addition, hBD-1 and hBD-2 mRNA
expression was significantly lower in oral SCC as compared to
the normal oral epithelium [131]. An immunohistochemical
study indicated that well-differentiated SCCs showed strong
immunoreactivity for hBD-2 around keratin pearls, whereas
no immunoreactivity was observed in poorly differentiated
SCCs. Keratin pearl formation with SCC tends to induce a
more intense expression of hBD-2 at both peptide and mRNA
levels. In contrast, hBD-2 peptide and its mRNA are unde-
tected in poorly differentiated SCCs [132]. Similar results are
obtained in cervical cancer [133]. In general, poorly differ-
entiated SCCs have a more aggressive course and worse
prognosis than well-differentiated SCCs. These results sug-
gest that hBD deficiency leads to the formation of microbial
colonies, which in turn induces inflammation and promotes
tumor progression.
We have demonstrated that the expression of hCAP18/LL-
37 mRNA is undetected in 16 cell lines from human oral SCC
(data unpublished). A similar result is obtained in that
hCAP18/LL-37 peptide expression is decreased in colonic
epithelial cancer cells than in the normal colonic tissue. In
addition, it is demonstrated by using an in vitro model of
76 K. Okumuracolon epithelial cell differentiation that the expression of
hCAP18/LL-37 mRNA and its protein increase during differ-
entiation [51]. These results indicate that cell differentiation
may be a determinant for the upregulation of epithelial
hCAP18/LL-37 expression.
Conversely, hCAP18/LL-37 is highly expressed in human
breast cancer cells with a correlation between its peptide
protein levels and tumor grade than normal mammary tissue
[134]. In addition, hCAP18/LL-37 is highly expressed in breast
cancer, correlating with the expression of the ERBB2 gene; its
peptide amplifies mitogen-activated protein kinase (MAPK)
signaling through ErB2 and treatment with the LL-37 peptide
stimulates migration of cancer cells [135]. Similarly, hCAP18/
LL-37 is significantly overexpressed in ovarian cancer cells;
its peptide induces ovarian cancer cell proliferation, migra-
tion, invasion, and matrix metalloproteinase (MMP) activa-
tion through formyl peptide receptor-like 1 (FPRL1) signaling
[136,137]. Furthermore, the hCAP18/LL-37 peptide is
expressed mostly in human lung cancers. Overexpression
of hCAP18/LL-37 in lung cancer xenografts increases the
formation of significantly larger tumors in nude mice
[138]. Collectively, these results suggest that hCAP18/LL-
37 is an autocrine survival factor released by cancer cells.
However, the involvement of hCAP18/LL-37 in human
OSCC remains to be elucidated. Further study is needed to
clearly understand this phenomenon.
Therapeutic potential of HDPs
(cathelicidin-based agents)
HDPs exhibit broad-range antimicrobial activity and a low
probability of resistance development [139]. They represent
ideal potential therapeutics. However, several issues stand in
the way of their development; the difficulty and high cost of
manufacturing peptides is arguably the principal problem
preventing the widespread clinical use of this class of anti-
microbial therapeutics [140].
In the oral cavity, HDPs, including the hCAP18/LL-37
peptide, play important roles in maintaining oral health.
Therapeutic use of HDPs in oral care requires clinical studies
with defined end points due to the complexity of the etiology
and pathogenesis of oral complications. Human trials failed
to support the use of isegenan (protegrin variant), as cathe-
licidin family peptide to reduce the severity of oral mucositis
[141], although microbial limit testing and safety studies
clearly indicated the efficacy of histatin in animals
[142,143]. In addition, adsorption of histatin 5 onto a poly
(methyl methacrylate) denture base can prevent C. albicans
biofilm formation, thus serving to reduce denture-induced
stomatitis [144]. Recently, it was shown that hCAP18/LL-37
potently inhibited the formation of Pseudomonas aeruginosa
biofilms in vitro. This occurred at a very low and physiolo-
gically meaningful concentration of 0.5 mg/ml, far below
that required to kill or inhibit growth [145].
Although lactoferrin (LF), an iron-binding glycoprotein, is
originally identified as an HDP, in addition to antimicrobial
activity and immunomodulatory functions, it also displays
antitumor activity. LF has been shown to have anti-cancer
activity in various malignant tumors [146]. For example,
talactoferrin (TLF), a recombinant human lactoferrin, is an
immunomodulatory molecule that has shown promising anti-tumor activity in preclinical models and in a variety of solid
tumors. Phase II trial data suggested that TLF is a promising,
well-tolerated agent that has demonstrated evidence of
potential clinical activity in metastatic renal cell carcinoma
[147].
Cationic antimicrobial peptides, including human cathe-
licidin hCAP18/LL-37, possess qualities that make them
excellent candidates for antimicrobial therapeutics, includ-
ing a broad spectrum of antimicrobial activity, ease of synth-
esis, and a novel mechanism of action. In a recent report, it
was shown that in bacterial infections with Shigella, expres-
sion of hCAP18/LL-37 and hBD-1 is reduced or turned off,
which could partly explain the chronic inflammatory
response associated with Shigella infection. Remarkably,
the study further demonstrated that plasmid DNA released
from lysed bacteria by the action of hCAP18/LL-37 was a
major mediator of antimicrobial peptide down-regulation
[148]. Therefore, hCAP18/LL-37 can act as a nuclear locali-
zation signal to translocate antisense nucleic acids [149].
Interestingly, a recent study demonstrated that treatment
with a combination of CpG oligodeoxynucleotides (CpG-
ODN), broadly as immunostimulant, and LL-37 generated
significantly better antitumor therapeutic effects and
enhanced survival in murine ovarian tumor-bearingmice than
treatment with CpG-ODN or LL-37 alone [150]. The expres-
sion of CD69 and IFN-g in NK cells stimulated by CpG-ODNs
can be enhanced by treatment with the LL-37 peptide, thus
leading to the activation of NK cells. NK cells play a critical
role in the antitumor effects against murine ovarian tumor.
Although HDPs, including hCAP18/LL-37, indicate antimi-
crobial and antitumor activity, it is currently difficult to
develop peptide-based drugs due to poor pharmacokinetics
and potential systemic toxicity [151].
Conclusion
Cathelicidins are an important family of HDPs because they
are multifunctional, and their significance in human immune
defenses is only beginning to be fully recognized. Addition-
ally, hCAP18/LL-37 elicits complex responses in many cell
types, either directly or through the modulation of cellular
responses to microbial compounds and other immune med-
iators. Their HDPs may be useful in the diagnosis and therapy
of periodontal and cariogenic diseases and in oral mucositis.
Further advances in our understanding of the biological
activity of HDPs, including hCAP18/LL-37, will be of thera-
peutic potential in infectious, inflammatory, and cancerous
diseases.
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